Finance

Beta
Lists
BCAX:NASDAQ
Bicara Therapeutics Inc
$29.00
+0.31%
(+0.090) 1D
$29.00
0.00% (0.00)
After hours
Closed: Jul 2, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BCAX...
Open
$29.13
High
$29.78
Low
$28.65
Mkt. cap
1.91B
Avg. vol.
802.78K
Volume
924.14K
52-wk high
$29.90
52-wk low
$8.74
EPS
-$2.77
Shares outstanding
65.70M
No. of employees
103
Open
$29.13
High
$29.78
Low
$28.65
Mkt. cap
1.91B
Avg. vol.
802.78K
Volume
924.14K
52-wk high
$29.90
52-wk low
$8.74
EPS
-$2.77
Shares outstanding
65.70M
No. of employees
103
News stories
From sources across the web
About Bicara Therapeutics Inc
CEO-
Employees103
Founded2018
HeadquartersBoston, Massachusetts, United States
SectorBiotechnology
Websitebicara.com
Analyst ratings
Based on 11 analysts giving stock ratings to BCAX in the past 3 months
Strong buy
Buy
9
Hold
2
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for BCAX in the last 3 months.
Highest
Current $29.00
$46.00 (+58.62%)
Average
$32.11 (+10.72%)
Lowest
$16.00 (-44.83%)
Analyst
Recommendation
Action
Price target
Projected
Date
Tazeen Ahmad
Bank of America Securities
Buy
Maintained
-
-
06/02/2026
Rajan Sharma
Goldman Sachs
Hold
Maintained
$18.00
-37.9%
06/01/2026
Richard Law CFA
Goldman Sachs
Hold
Maintained
$18.00
-37.9%
06/01/2026
Eva Fortea Verdejo
Wells Fargo
Hold
Reiterated
$16.00
-44.8%
06/01/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$42.00
+44.8%
06/01/2026
Unknown Analyst
Wedbush
Buy
Maintained
$30.00
+3.4%
05/26/2026
Bradley Canino
Guggenheim
Buy
Maintained
$42.00
+44.8%
05/26/2026
Boris Peaker
JonesTrading
Buy
Maintained
$30.00
+3.4%
05/22/2026
Stephen Willey
Stifel Nicolaus
Buy
Maintained
$46.00
+58.6%
05/12/2026
Judah Frommer
Morgan Stanley
Buy
Reiterated
$37.00
+27.6%
05/12/2026
Jeet Mukherjee
BTIG
Buy
Reiterated
$28.00
-3.4%
05/11/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/11/2026
Soumit Roy
JonesTrading
Buy
Maintained
$30.00
+3.4%
04/06/2026
Reni Benjamin
Citizens JMP
Buy
Initiated
$31.00
+6.9%
01/29/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
24.80M
32.98M
32.99M
47.50M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.22M
7.70M
8.13M
12.74M
Operating expense
32.02M
40.68M
41.12M
60.24M
Total operating expenses
32.02M
40.68M
41.12M
60.24M
Operating income
-32.02M
-40.68M
-41.12M
-60.24M
Other non operating income
-
-
-
-
EBT including unusual items
-27.34M
-36.29M
-37.33M
-56.16M
EBT excluding unusual items
-27.34M
-36.29M
-37.33M
-56.16M
Income tax expense
52.00K
40.00K
53.00K
52.00K
Effective tax rate
-0.19%
-0.11%
-0.14%
-0.09%
Other operating expenses
-
-
-
-
Net income
-27.39M
-36.33M
-37.39M
-56.21M
Net profit margin
-
-
-
-
Earnings per share
-0.50
-0.67
-0.68
-0.93
Interest and investment income
4.68M
4.39M
3.79M
4.08M
Interest expense
-
-
-
-
Net interest expenses
4.68M
4.39M
3.79M
4.08M
Depreciation and amortization charges
-
-
-
-
EBITDA
-32.00M
-40.65M
-41.08M
-60.20M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create portfolio
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer